Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.95 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.71 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.71 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.50 |
| ▸ | GGT1 | P19440 | 2/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL247522 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL28611427 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL15951718 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL16893974 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL16893976 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL3338788 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL27850644 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL4594997 | 0.97 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL25241602 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL20362356 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496026-A | Composite material for improving reinforcement and carbonization resistance of alkali-activated cementing material and preparation method thereof | 东南大学 | 2023-07-28 | — | — | CN | claimed |
| EP-3799864-B1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | INTAS PHARMACEUTICALS LTD (IN) | 2023-03-01 | — | — | EP | claimed |
| EP-4041199-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | Intas Pharmaceuticals Ltd. (IN) | 2022-08-17 | — | — | EP | claimed |
| US-20220226368-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | INTAS PHARMACEUTICALS LIMTED (IN) | 2022-07-21 | — | — | US | claimed |
| CN-112760279-A | Mesenchymal stem cell culture medium | 圣美基因科技(北京)有限公司 | 2021-05-07 | — | — | CN | claimed |
| WO-2021064636-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | INTAS PHARMACEUTICALS LTD. (IN) | 2021-04-08 | — | — | WO | claimed |
| EP-3799864-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | Intas Pharmaceuticals Limited (IN) | 2021-04-07 | — | — | EP | claimed |
| EP-3082778-B1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2019-04-03 | — | — | EP | claimed |
| US-20150197483-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIHYDROCHLORIDE | WARSAW ORTHOPEDIC, INC. (US) | 2015-07-16 | — | — | US | claimed |
| CN-103951572-A | Separation and purification process for producing branched chain amino acid by using fermentation method | WUXI JINGHAI AMINO ACID CO LTD | 2014-07-30 | — | — | CN | claimed |
| EP-1254092-B1 | RESOLUTION OF DL-RACEMIC MIXTURES | DEGUSSA (DE) | 2004-01-21 | — | — | EP | claimed |
| US-6673942-B1 | PREFERENTIAL CRYSTALLIZATION, PHYSICAL SEPARATION | DEGUSSA AG (DE) | 2004-01-06 | — | — | US | claimed |
| EP-1254092-A1 | RESOLUTION OF DL-RACEMIC MIXTURES | Degussa AG (DE) | 2002-11-06 | — | — | EP | claimed |
| WO-2001058835-A1 | RESOLUTION OF DL-RACEMIC MIXTURES | DEGUSSA AG (DE) | 2001-08-16 | — | — | WO | claimed |
| EP-0719148-B1 | ORAL WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE DERIVATIVE AND CALCIUM SALT | DEGHENGHI ROMANO (CH) | 1998-02-18 | — | — | EP | claimed |
| EP-0719148-A1 | ORAL WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE DERIVATIVE AND CALCIUM SALT | DEGHENGHI, Romano (CH) | 1996-07-03 | — | — | EP | claimed |
| US-5480574-A | 2-aminocarboxylic acid hydrochloride compositions for removal of hard-water deposits | SINGERMAN GARY M (US) | 1996-01-02 | — | — | US | claimed |
| WO-1995007701-A1 | ORAL WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE DERIVATIVE AND CALCIUM SALT | DEGHENGHI ROMANO (CH) | 1995-03-23 | — | — | WO | claimed |
| US-20260041620-A1 | NOVEL AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITY | SYTHEON LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-3960942-A | Leucine isoleucine separation | SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS (CH) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197483-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIHYDROCHLORIDE | ALKBH3, AADAT, ALKBH1 | PTGS1 2378/4885SLC7A5 1032/4885SLC1A2 412/4885 |
| US-20260041620-A1 | NOVEL AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITY | TYR, ARG2, BCAT2 | PTGS1 2707/4885SLC7A5 180/4885SLC1A2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.